Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer

 Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of
                              Colorectal Cancer

Cambridge, Massachusetts Mayor Signs Proclamation Declaring March 6 Colorectal
Cancer Awareness Day

PR Newswire

CAMBRIDGE, Mass., March 6, 2013

CAMBRIDGE, Mass., March 6, 2013 /PRNewswire/ -- In honor of National
Colorectal Cancer Awareness Month, Sanofi (EURONEXT: SAN and NYSE: SNY) and
the Colon Cancer Coalition/Get Your Rear in Gear have collaborated to raise
awareness of colorectal cancer in Cambridge, Massachusetts by asking the Mayor
to sign a proclamation decreeing today, March 6 as Colorectal Cancer Awareness
Day in Cambridge. Sanofi Oncology and Get Your Rear in Gear are encouraging
the local community to get screened for colorectal cancer and maintain a
healthy lifestyle as a means of prevention and early detection.  

"I applaud Sanofi Oncology and Colon Cancer Coalition on their collaborative
efforts to raise awareness of colorectal cancer in the Cambridge community,"
said Henrietta Davis, Mayor of the City of Cambridge. "Educating our citizens
on prevention and early detection of colorectal cancer is key to fighting this
terrible illness."

"We're proud to partner with Sanofi Oncology to raise awareness of colorectal
cancer," said Anne Carlson, Executive Director, Colon Cancer Coalition/Get
Your Rear in Gear. "I know that patients and caregivers appreciate the efforts
undertaken to proclaim Colorectal Cancer Awareness Day in Cambridge, as it
provides a voice to spread the word about colorectal cancer."

Today's proclamation underscores Sanofi Oncology's ongoing commitment to the
Cambridge community, as evidenced through the company's strong business
presence and research partnerships with local academia, hospitals, biotech and
research institutions. Sanofi Oncology currently has nine partnerships ongoing
in the Cambridge area alone.

"At Sanofi Oncology, our mission goes beyond developing innovative medicines
and ensuring their availability," said Debasish Roychowdhury, M.D., Senior
Vice President and Head, Sanofi Oncology. "Through initiatives like today's
proclamation ceremony, we're educating patients and the public about various
cancers, prevention, and treatments, to ultimately promote a healthy way of
life in the Cambridge community."

About Colorectal Cancer

In 2010, 142,570 new cases were diagnosed and 51,370 people died from
colorectal cancer in the United States. When colorectal cancer is diagnosed at
an early stage, the five-year survival rate is nearly 90 percent. However,
when the cancer is not diagnosed until a late state, the five-year survival
rate is closer to 10 percent. In the past ten years, colon cancer screening
rates have increased, but rates still remain low, especially among the
uninsured. According to the American Cancer Society, men and women should
begin screening for colon cancer at age 50. If the entire population was
screened at that age, the number of colorectal cancer-related deaths would be
cut in half.

About the Colon Cancer Coalition /Get Your Rear in Gear

Get Your Rear in Gear^® events are presented nationally by the Colon Cancer
Coalition, a non-profit organization based in Minneapolis. The events are 100%
volunteer-driven in communities throughout the United States. The Colon Cancer
Coalition distributes funds raised at Get Your Rear in Gear events back into
local communities for colon cancer education, prevention, and screening. By
making the words colon, colorectal and colonoscopy a part of the everyday
language, we believe we can overcome the fear and decrease deaths from this
largely preventable cancer.  A history of the organization, upcoming events,
and a list of programs receiving funding from the Colon Cancer Coalition can
be found at GetYourRearinGear.com.

About Sanofi Oncology

At Sanofi Oncology, the patient is our inspiration. We are dedicated to
translating science into effective therapeutics that address unmet medical
needs for cancer and organ transplant patients. Through our global
organization of talented and passionate employees, we are building a renewed
and diversified portfolio, driven by the principles of innovation,
personalization and patient access to medicines. We believe that delivering
innovative treatment solutions requires collaboration with external experts,
which is why we partner our own internal expertise with the best experts in
scientific discovery and clinical research around the world.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.  Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme.  Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements.  Forward-looking
statements are statements that are not historical facts.  These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance.  Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions.  Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements.  These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011.  Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

Contacts:

Sanofi Oncology Communications 
Lauren Musto                                                         
Tel: (617) 768-1993                                                 
E-mail: Lauren.Musto@sanofi.com                                

Colon Cancer Coalition/Get Your Rear in Gear
Erin Peterson                                                         
Tel: (651) 247-4023                                                 
E-mail: erinpeterson@getyourrearingear.com         

    

SOURCE Sanofi

Website: http://www.getyourrearingear.com